Immunovant (IMVT) Proxy Filing summary

Executive summary

• Annual meeting scheduled for August 12, 2024, with virtual attendance available for shareholders.

• Shareholders are encouraged to review proxy materials and vote by August 11, 2024, 11:59 PM EDT.

Voting matters and shareholder proposals

• Election of three directors to serve until the 2025 Annual Meeting: Peter Salzmann, George Migausky, and Douglas Hughes.

• Ratification of Ernst & Young LLP as independent auditor for the fiscal year ending March 31, 2025.

• Advisory vote to approve executive compensation for named executive officers.

• Proxy holders may vote on other business arising at the meeting.

Board of directors and corporate governance

• Board recommends voting in favor of all director nominees and proposals.